Our data revealed, for the first time in GBM, a striking alteration in relevant routes closely associated with GBM progression and initiation, especially the AKT-mTOR and ß-catenin signaling pathways [12, 37, 46, 56], in response to SF3B1 blockade. The gene discussed is AKT1; the disease is glioblastoma.